The 1 analysts offering 12-month price forecasts for Brooklyn Immunotherapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +488.24% increase from the last price of 0.51.
The current consensus among 1 polled investment analysts is to Buy stock in Brooklyn Immunotherapeutics Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.13
Reporting Date Aug 15
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.